Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859643 | 0.89 | NOTUM (0.45) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL28934829 | 0.85 | NOTUM (0.49) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL23059425 | 0.85 | NOTUM (0.43) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL22480272 | 0.85 | NOTUM (0.43) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL25884465 | 0.84 | NOTUM (0.42) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL24036185 | 0.84 | NOTUM (0.48) | NOTUMCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL20857112 | 0.82 | NOTUM (0.47) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL29065096 | 0.82 | NOTUM (0.47) | NOTUMCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL20857078 | 0.82 | NOTUM (0.40) | NOTUMCPB2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL20857079 | 0.82 | NOTUM (0.40) | NOTUMCYP1A2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081310-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081309-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024006544-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006551-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023147053-A2 | THERAPIES FOR MUCOPOLYSACCHARIDOSIS TYPE 6 | SIGILON THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147042-A2 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING CNS DISORDERS | SIGILON THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023129738-A2 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129726-A2 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023076620-A1 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021102271-A1 | MONOCLONAL CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2021062273-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | SIGILON THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2020198685-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | TGFB2, TGFB1, COL2A1 | NOTUM 2611/4885CPB2 323/4885CYP1A2 495/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | NOTUM 4762/4885CPB2 718/4885CYP1A2 3887/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | NOTUM 4713/4885CPB2 2372/4885CYP1A2 4800/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | NOTUM 4609/4885CPB2 462/4885CYP1A2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.